BioCentury
@BioCentury
Followers
15,841
Following
1,893
Media
877
Statuses
37,684
The leading voice for decision-makers throughout the global biopharma ecosystem. Follow us on LinkedIn for exclusive insights & analysis:
Redwood City, Calif.
Joined December 2010
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
無課金おじさん
• 329268 Tweets
Algeria
• 276565 Tweets
Be Mine
• 196847 Tweets
billie
• 139960 Tweets
Charli
• 102852 Tweets
バニーの日
• 100665 Tweets
English Version
• 97153 Tweets
Bears
• 84916 Tweets
Merry Christmas
• 58048 Tweets
日経平均
• 38437 Tweets
ユアネクスト
• 37954 Tweets
僕のヒーローアカデミア
• 36370 Tweets
ヒロアカ
• 34021 Tweets
赤の救助隊
• 33102 Tweets
性分化疾患
• 29532 Tweets
NISA
• 26877 Tweets
ダンジョンの中のひと
• 23122 Tweets
パンツの日
• 21245 Tweets
#يوم_الجمعه
• 16494 Tweets
長岡花火
• 16133 Tweets
八村離脱
• 15704 Tweets
ポケダン
• 13705 Tweets
ダイエットボイス
• 10656 Tweets
Last Seen Profiles
How NCI's cancer-focused national lab is stepping up to validate
#COVID19
serological tests, uncover genetics of severe disease and find covalent inhibitors of viral proteins
2
22
47
Fred Frank, co-founder of the biotech industry, is dead at 89.
1
7
34
With ALS action plan,
@US_FDA
aims for patient engagement, but
#ALS
advocates such as
@iamalsorg
's
@bsw5020
say the blueprint lacks urgency, noting that the agency’s timeline exceeds the life expectancy of most current patients
3
15
33
#ALS
community ends year with a win at the White House as
#ACTforALS
becomes law, earmarking $100M annually to increase access to therapies
3
21
33
Rising serial entrepreneur Akiko Iwasaki has shown that increasing lymphatic drainage in the brain can prime immune responses to clear brain tumors. The work could lead to third cancer start-up out of
@VirusesImmunity
's lab this year.
0
7
30
Roche is looking to make CNS a growth driver to match oncology this next decade. Partnering with small and large companies will be a big part of that.
1
12
29
ICYMI: Formed by
@kiranshaw
, Kush Parmar and
@DrSidMukherjee
, Bangalore's Immuneel plans to bring a
#CART
therapy to cancer patients in India for about $50K per treatment
4
12
28
ICYMI: The last two decades of drug approvals suggest the
#RuleofFive
is losing its grip on medicinal chemistry. Is it time to abandon the concept of "drug-like properties"?
@Novartis
@abbvie
3
20
24
Immuneel, India cancer cell therapy co from
@kiranshaw
, Kush Parmar and
@DrSidMukherjee
, in-licenses its first CAR T therapy.
0
8
24
Into
#NKcells
before they were cool:
@affimed
's long journey to find the right settings and combinations for its innate cell engager bispecifics is finally getting investors' attention; story from
@StephenPHansen
in
@BioCentury
0
6
25
Targeted degradation steps out of cellular bounds with new platforms from the labs of
@ArvinasInc
founder
@CraigMCrews
and
@Palleon_Pharma
founder
@CarolynBertozzi
0
7
24
Why
@scrippsresearch
consolidated three institutes, created a non-profit portfolio fund and doubled down on phenomics-based target discovery.
0
10
22
Bob Nelsen, co-founder of Arch Ventures Partners, on AI creating a "language of biology," responding to the China challenge, and focusing on big opportunities.
0
5
22
Luciana Borio (
@llborio
) joins Arch as venture partner, brings expertise, FDA, White House experience in biodefense and public health and will focus on manufacturing, clinical trials, novel therapies. Firm promotes Carol Suh to partner
2
3
21
FDA Commissioner
@SGottliebFDA
wants bang for regulatory buck, via interview with BioCentury's
@steveusdin1
.
0
14
18
How
@Immunocore
’s $100M deal with
@Genentech
gives the
#TCR
bispecific play enough runway to justify its lofty valuation.
@StephenPHansen
explores in this week’s BioCentury
0
10
20
Kymera's latest Ph I data shows its IRAK4 protein degrader KT-474 reaches 96% degradation and inhibits induction of eight pro-inflammatory cytokines $KYMR
0
4
18
There are now eight
#COVID19
vaccines in the clinic: a graphical comparison of the current clinical vaccine modalities.
1
9
19
ICYMI: In a Guest Commentary,
@ScottGottliebMD
says
@US_FDA
is “on the cusp of a major cultural shift” that will transform the way the agency reviews drugs.
1
10
19
Merck acquires Calporta for up to $576 million, one of eight companies from the $GSK-Avalon Ventures' 2013 build-to-buy deal. Calporta is developing
#TRPML1
agonists for lysosomal storage and neurodegenerative disorders like
#alzheimers
and
#parkinsons
0
8
18
Over 200 COVID-19 trials could read out this summer; BioCentury breaks them down by therapeutic mechanism, size, phase and comparator.
0
15
18
.
@atlasventure
's Bruce Booth sees biotech's belt-tightening starting to yield more favorable financing environment, but there's still pain to come. + how new modalities will play out. Watch
@LifeSciVC
in conversation
@BioCentury
's
@FishburnSimone
0
3
17
Data Byte: Phase I data suggest Inovio's
#COVID19
vax is more effective at stimulating T cells than neutralizing antibody responses $INO
2
6
16
Exclusive fireside chat with
@FishburnSimone
reveals how
@Roche
pharma’s years-long pursuit of
@ArrakisTx
finally yielded one of the largest early-stage deals it has ever entered
@michael_gilman
#COVID19
Listen now:
0
3
17
Biocon’s path to affordable innovation: A conversation with Kiran Mazumdar Shaw on
#TheBioCenturyShow
.
@kiranshaw
@BioconBiologics
2
8
17
BMS is paying Agenus $200M up front for global rights to a bispecific antibody targeting TIGIT $AGEN
1
7
15
Check out the
#JPM2021
Guide that
@macbiocom
and BioCentury have teamed up to create
#JPM21
#Biotechshowcase
#healthcarepartneringweek
@pharmaceutical
0
4
16
@NPLB_org
proposes updated cost-effectiveness methodology that accounts for disease severity, loss of market exclusivity and social value
0
9
15
Ocrevus, an injectable, has overturned the "small molecule is better" paradigm in MS. What does that mean for the next drugs coming to market? $NVS $CELG
2
5
16
ICYMI: BioCentury Innovations'
@Laurenmmartz
explores why new targets at
#AACR18
suggest non-coding RNAs are on the rise
0
4
16
Hereditary angioedema proves to be an ideal proof-of-concept indication for in vivo gene editing from
@intelliatx
with new NTLA-2001 supporting a clear dose response in gene expression and near flawless clinical efficacy in first 10 patients
0
2
15
10 PDUFA dates on deck in November: a BioCentury data byte $ETON $LQDA $BMRN $AADI $FENC $LEGN $JNJ $AMYT $BYSI $CTIC $VBIV
0
4
15
From dinner in Basel to Zoom under lockdown: James Sabry and
@michael_gilman
talk to Editor in Chief
@FishburnSimone
about how the Roche-Arrakis deal came about.
@ArrakisTx
@Roche
0
6
14
GI Band-Aid: How preventing bacteria from escaping the gut could treat autoimmunity
1
12
14
How new
@Medicxi
company Divide & Conquer, co-founded by
@sciencescanner
, aims to capitalize on new biology that could prevent cancer cells from sharing resistance mechanisms via multicellular networks
0
11
15
#ALS
patients are demanding greater regulatory flexibility from FDA that would enable broader access to therapies in the clinic. Doing so could generate a wealth of data
@iamalsorg
@alsassociation
5
8
15
In this week's
@BioCentury
,
@StephenPHansen
looks at why
@medicxi
committed up to EUR 40M to spin out two orexin agonist programs from
@soseiheptaresco
0
4
14
BIO launches a
#COVID19
vaccine facts website to provide vaccine education through trusted messengers.
@IamBiotech
0
8
15
Antibody-drug conjugates outnumber traditional antibodies in BioCentury's translational trend analysis based on first-in-human abstracts at
#AACR23
0
2
15
BioCentury's
#ASCO18
abstract roundup suggests that away from the PD-1 herd, researchers are trying many new strategies, modalities and targets to solve big problems in cancer
0
13
14
Anti-China bills portend massive blow to biotech. According to a BioCentury survey, an overwhelming majority of biotechs expect pipeline setbacks; many oppose BIO’s reversal
0
9
13
Gilead's antiviral remdesivir almost completely resolved the symptoms of a U.S. patient infected with the coronavirus; now the biotech is planning a Chinese trial $GILD
#2019nCov
1
4
14
5AM Ventures closes 5AM Opportunities I fund and 5AM Ventures VI fund, raising total of $497 million.
1
7
14
Biogen's SMA therapy Spinraza yields long-term preservation of motor development and function on par with Zolgensma gene therapy data. $BIIB
0
5
13
How Nektar’s PEGs turned IL-2 into a viable immunotherapy partner for BMS
0
7
13
#2019nCoV
diagnostics, critical for patient care and public health, are starting to be deployed widely
0
4
11
ICYMI:
@MIT
Professor Christopher Love's latest foray into benchtop manufacturing of biologics has yielded the InSCyT system, which produces clinical-quality proteins in just three days, suggesting it is nearly ready for industry use.
0
5
13
Remembering Fred Frank, a giant of biotech:
@jmaxlevin
,
@ps_onlyconnect
pay tribute to Frank, investment banker and early architect of the biotech industry
0
6
13
Lining up efficacy and immunogenicity data from the first
#COVID19
vaccines reveals the first hints of correlates of protection
0
13
13
Drive-by analysis of accelerated approval is intellectual malpractice. Medical journals and news publications have incorrectly concluded that half of cancer accelerated approvals are useless. BioCentury's
@steveusdin1
explains why.
1
10
13
The latest revival of 38-yr-old $CLDX comes on the back of urticaria program CDX-0159, with Ph Ib data presented at
#EAACI2021
showing 95% complete response rate.
@StephenPHansen
speaks with
#Celldex
CEO Anthony Marucci and CSO Tibor Keler
0
4
12
.
@biogen
may have called off trials of aducanumab, but the amyloid hypothesis of Alzheimer's disease lives on.
@BioCentury
's
@SelinaMKoch
asks companies what data could make them walk away.
1
4
12
.
@PureTechH
subsidiary Vor's engineered HSCs platform could eliminate on-target toxicity for CAR Ts and open up new targets for non-B cell cancers
0
8
12
FDA Commissioner
@DrCaliff_FDA
calls misinformation "leading cause of death," vows plan to combat it.
3
4
11
The Quiet Disrupters: How a technology to encode mAbs in RNA or DNA is quietly growing, with the potential to upend the standard way biologics are manufactured.
1
7
11
.
@ARPA_H
backs
@EveryCure
's drug- and disease-agnostic approach to drug repurposing with $48.3M
#rarediseaseday2024
#raredisease
0
3
12
.
@ScottGottliebMD
sits down with
@steveusdin1
to discuss pandemic preparedness, regulatory innovation and FDA’s future during
#BioCenturyShow
tomorrow >> Register for open access:
@US_FDA
@pharmaceutical
#pandemic
#biotech
#lifesciences
#FDA
0
8
12
ICYMI: Solid hopes: Next-gen T cell bispecifics hope solid tumor success can differentiate them from CAR Ts and checkpoint inhibitors
0
4
12
A trial funded by
@CureDuchenne
,
@MDAorg
and
@ParentProjectMD
aims to solve the AAV redosing problem. If successful, it could have major impact on patient care and gene therapy pipeline strategies.
0
6
12
Congrats to the 2019 BayHelix China Healthcare Award winners, announced last week during the 6th BioCentury-BayHelix China Healthcare Summit in Shanghai. $BGNE $AMGN $FGEN $ZLAB
0
2
11
#FTC
report highlights role of small companies in developing drugs, makes case that large companies acquiring small companies supports innovation.
0
6
12
In a first, FDA recognizes genetic database, removing regulatory hurdle
0
3
11
With
@US_FDA
's approval of tofersen from
@Biogen
,
@ionispharma
, neurofilament becomes ‘anchor’ biomarker in
#ALS
0
8
11
Trading of Everest's shares is to begin Friday in Hong Kong after the mainland China company priced what could become the biggest IPO yet since
@HKEXGroup
opened its biotech chapter in 2018
0
7
11
.
@JMaraganore
talks to
@FishburnSimone
on The BioCentury Show about the convergence of an innovation explosion and a rising bar for investment, and why that's good for biotech. Plus, views on the Inflation Reduction Act, Biosecure Act, and more.
0
5
11
Gap in early stage funding for antibiotics companies leads
@NovoHoldings
to launch $165M REPAIR Impact Fund to invest in antimicrobial resistance plays
0
5
11
How OSI has leveraged a foundational deal with
@UniofOxford
into an $800M+ evergreen fund and an expanding life sciences portfolio. BioCentury's
@StephenPHansen
speaks with OSI's Lachlan MacKinnon &
@UcianeScarlett
.
@OSI_Updates
0
3
11
New CAR designs at
#ASH18
: BioCentury's infographic highlights CARs designed for multi-antigen targeting, overcoming PD1 and boosting tumor homing, and shows where to find them.
2
3
11
Formed by
@kiranshaw
, Kush Parmar and
@DrSidMukherjee
, Bangalore's Immuneel plans to bring a
#CART
therapy to cancer patients in India for about $50K per treatment
1
4
11
BioCentury launches free
#COVID19
Resource Center for the biomedical community to aid in the development of
#coronavirus
countermeasures and to help companies navigate the business impacts during the crisis
0
11
11
Can CAR T cells move beyond cancer? The answer might depend on whether allogeneic technologies take off
0
5
10
How data from past trials, RWD and simulations are are being deployed to build external control arms for clinical trials
0
7
10
.
@healx
has an AI-based platform to repurpose drugs for rare disease and is building the patient voice into its discovery process. The $56M series B round the U.K. company raised Wednesday will help bring its
#FragileXSyndrome
into the clinic
0
4
10
BioCentury proudly supports
@kendallsqorch
and their
#Symphony
for Science 2022 in
#Boston
benefiting
@SCFG
!
Tickets are on sale now at
0
4
10
How lymphatics discoveries could yield new opportunities for PureTech
0
5
10
As
@CEPIvaccines
looks to prepare for the next pandemic, it has set a lofty goal to reduce to 100 days the time from sequencing the pathogen to a regulatory submission of a vaccine. But, what will it take?
0
3
10
ICYMI: For first-time academic entrepreneurs, the challenge is establishing industry bona fides
0
3
10
EXCLUSIVE: Gottlieb’s Exit Interview. Just days after his resignation,
@ScottGottliebMD
talks with BioCentury’s
@steveusdin1
about what he's done, what he thinks was most important, and what will carry forward. (Read with subscription or trial sub.)
0
13
8
BioCentury maps readouts from COVID-19 clinical trials to disease stage and therapeutic mechanism.
0
7
10
POC for cytokines: Cytokines are emerging as a logical combination partner to boost PD-1 responses
0
4
10
Codiak and Sarepta team up to develop AAV-stuffed exosomes for repeat dosing of nucleic acid therapies. $SRPT
0
2
10
How academics are helping companies harness the microbiome for immuno-oncology
0
2
10
How drug developers are thinking about the recent report of the surprising marriage of carbohydrates and RNA.
0
4
10
Four of the leading COVID-19 potential vaccines and antibody therapies have their roots in
@DARPA
, BioCentury reports
#coronavirus
#Covid_19
@NIH
@moderna_tx
@InovioPharma
@AbCelleraBio
@Vir_Biotech
0
8
8
.
@BioCentury
's annual
@ASCO
preview shows how bispecifics and CAR T cells stack up by the numbers in solid tumor indications.
0
5
9